The Federal Trade Commission has reached a tentative settlement with the Big 3 PBM Caremark, which should increase the PBM’s transparency and has the potential for further reducing the use of rebate-based pharmaceutical pricing models. In the latest salvo in the Federal Trade Commission’s (FTC’s) war on PBM practices, begun in 2024, it has reached … Continue reading Another Big 3 PBM Settles With FTC on Rebates, Passthroughs, and Price Spreads
Copy and paste this URL into your WordPress site to embed
Another Big 3 PBM Settles With FTC on Rebates, Passthroughs, and Price Spreads
The Federal Trade Commission has reached a tentative settlement with the Big 3 PBM Caremark, which should increase the PBM’s transparency and has the potential for further reducing the use of rebate-based pharmaceutical pricing models. In the latest salvo in the Federal Trade Commission’s (FTC’s) war on PBM practices, begun in 2024, it has reached … Continue reading Another Big 3 PBM Settles With FTC on Rebates, Passthroughs, and Price Spreads